Bibliographic Details
| Title: |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. |
| Authors: |
Fischer T; Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA., Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ |
| Source: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2010 Oct 01; Vol. 28 (28), pp. 4339-45. Date of Electronic Publication: 2010 Aug 23. |
| Publication Type: |
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: |
Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
